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Object. Gender and disease course specific incidences were studied in high- and medium-risk regions of MS in Finland.Methods.
Age- and gender-specific incidences with 95% CIs were calculated in 10-year periods from 1981 to 2010. Poser diagnostic criteria
were used and compared with the McDonald criteria from 2001 to 2010. Association between age and diagnostic delay over time
was assessed by using the Kruskal-Wallis test. Results. 1419 (89%) RRMS and 198 (11%) PPMS cases were included. RRMS incidence
increased with the female to male ratio (F/M) from 4,2/105 (F/M 1.9) to 9,7 (2.3), while that of PPMS decreased from 1,2 (1.6) to 0,7
(1.2). The use of McDonald criteria did not change the conclusion. The decreasing diagnostic delay and age at diagnosis in RRMS
were associated within the 10-year periods and contrasted those in PPMS. Increasing female risk in RRMS was observed in the
high-risk region. Conclusion. Increasing RRMS incidence and high female ratios shown in each age group indicate gender-specific
influences acting already from childhood. A more precise definition of the risk factors and their action in MS is needed to provide
a better understanding of underlying pathological processes and a rationale for the development of new preventive and treatment
strategies.
1. Introduction
Increasing incidence in MS concerns the rising female to
male (F/M) ratio [1] and relapsing-remitting (RRMS) type of
the disease [2]. It has become apparent that environmental
factors play an active role, but little is known about the factors
that carry the gender- and disease-course-specific effects.The
accumulated evidence indicates that latitudinal, genetic, and
local environmental factors interact to causeMS, and a recent
study has confirmed that the latitudinal effects are becoming
more relevant at polar and intermediate latitudes for the RR
phenotype, particularly in women [2].
The clinical and pathological spectrum of multiple scle-
rosis is heterogeneous [3]. Different subtypes are believed
to share the same genetic architecture [4], and several lines
of evidence suggest that multiple sclerosis susceptibility
genes, particularly HLA-DRB1∗15, influence the phenotypic
expression of the disease, although some of the evidence
on this aspect of the disease is conflicting [5]. The majority
of MS cases may be classified as relapsing-remitting MS
(RRMS) from onset and, in about 10–30% of cases, as
primary progressiveMS (PPMS). Clinical differences indicate
a younger age at onset and female preponderance (F/M 2.2)
in RRMS versus low F/M ratios (about 1.3) and older age
in PPMS [6]. A unifying concept today holds that multiple
sclerosis can be considered as one disease with different
phenotypes [7].
The clinical segregation of disease courses is highly rele-
vant, as the current disease-modifying treatments (DMT) are
effective mainly against relapsing MS [8]. Recent changes in
diagnostic criteria forMS have addressed the need for reliable
disease type identification in MS. However, several issues
regarding PPMS recognition have remained [9], although
the criteria proposed in 2001 [10] and strict utilization of
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the latest McDonald criteria from 2010 [11] presumably
help in avoiding diagnostic errors. Recent observations have
pointed at stable incidence rates with PPMS, whereas RRMS
incidence rates are rising [12, 13].
Finland is a country in northern Europe between the
latitudes 60 and 70∘ and belongs to the high-risk areas of MS,
together with Nordic areas [2]. MS incidence has increased
significantly from 1981 to 2010 also in Finland, especially in
the high-risk regions [14]. The high-risk areas in Finland
are located in western Finland, especially in Seina¨joki and
Vaasa, where respective total incidences were 12.5 per 105
person-years and 8.3/105 in 2010. The MS risk was twofold
in Seina¨joki (SIR1.9) and significantly higher in Vaasa (1.2)
compared with neighboring Pirkanmaa (comparator, 1.0).
The incidence in Pirkanmaa was 6.7/105, which is regarded
as a medium-risk rate in Finland.
In this study we aim to study the disease-course- and
gender-specific incidence trends in the high-risk districts
of Seina¨joki and Vaasa and the medium-risk district of
Pirkanmaa, while also considering the effect of changing
diagnostic methods and criteria. In terms of the recent global
trends in MS, we assume that the increase in RRMS is also
seen in our study cohort. Given that the study populations
are genetically and socioeconomically stable, we hypothesize
that the environmental effects are reflected analogically in
incidences in the districts, which would reflect the action
of the underlying pathomechanism and common epigenetic
factors in risk groups.
2. Material and Methods
The National Institute for Health and Welfare and local
ethical standards committee approved retrospective scruti-
nizing of identified patient records in the hospitals under
the study. Residence of cases was updated by personalized
identification number and by year of diagnosis at Statistics
Finland (http://www.stat.fi/).
A detailed description of study population, case collec-
tion, and case ascertainment is presented elsewhere [14].Hos-
pital districts under the study belong to Tampere University
Hospital region in western Finland, shown in Figure 1. The
high-risk area comprises the Seina¨joki and Vaasa Central
Hospital districts and medium-risk area the Pirkanmaa
district. The total population in the districts was 850,630 in
2010. Neurological services for diagnosis and treatment are
evenly distributed among the hospitals. Magnetic resonance
imaging (MRI) has been available from 1990 in Pirkanmaa
and from 1993 in other hospitals.
Caseswere included in the analysis when they fulfilled the
criteria of clinically definite (CD) or laboratory-supported
definite (LSD) MS by Poser et al. [15] between 1 January
1981 and 31 December 2010 and resided in the study districts
in the year of diagnosis. Cases from 1 January 1981 to 31
December 2010 with diagnoses of morbus demyelinans and
optic neuritis (340, 341 in ICD 8-9, G35, G37.4, and H46
in ICD 10) were first identified from the registries in the
hospitals, where diagnosis was made by a neurologist. Patient
documents were then scrutinized by the authors (MH, AM,
and MLS). Case assessment included paraclinical tests and
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Figure 1: Map of Finland. Finland lies in Scandinavia, North
Europe, between latitudes 60 and 70∘N. Gulf of Bothnia in northern
part of Baltic Sea limits the west coast. The total population was
5.4 million in 2010. Locations of Central Hospitals in Seina¨joki
(dots) and Vaasa (dark grey) and University Hospital of Tampere at
Pirkanmaa district (oblique lines) are pointed in the map.
their time point, level, and results; forMRI, evoked potentials
(EP) including visual, brainstem auditory, and sensory EPs;
and cerebrospinal fluid (CSF). The year of onset and year of
definite diagnosis were recorded, and information on specific
onset symptoms was collected. The classification of disease
course was reevaluated to ascertain whether the criteria of
RRMS or PPMS were met [16]. To scrutinize the effect of
changing diagnostic methods and criteria in the cohort, we
reevaluated the cohort diagnosed from 2001 to 2010 by the
McDonald criteria presented in 2001 [10].
The distribution of onset symptoms was calculated by
disease course in the whole cohort. Initial MS symptoms
were categorized in the following groups: motor (including
pyramidal symptoms such as motor hemiparesis or paresis
in the upper limbs and medullary symptoms, mainly motor
paraparesis), brainstem (diplopia, trigeminal sensory symp-
toms, or facial dysfunction), visual (disturbances seen in
optic or retrobulbar neuritis), sensory, and other symptoms
(cerebellar dysfunction, fatigue or psychiatric problems, and
epileptic seizures).
Age-adjusted gender- and disease-course-specific inci-
dence rates per 105 person-years were calculated with a 95%
confidence interval (CI) from 1 January 1981 to 31 December
2010, and this period was divided into three subperiods:
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Table 1: Age-adjusted incidence of RRMS and PPMS per 105 person-years with 95% CIs and F/M ratios from 1981 to 2010 in ten-year periods.
Disease course RRMS PPMS
Period Person-years Number of new cases Incidence F/M Number of new cases Incidence F/M
I 95% CI I 95% CI
1981–1990 6208067 280 4.2 3.7–4.6 1.9 80 1.2 0.9–1.4 1.6
1991–2000 6142661 526 8.5 7.8–9.2 2.0 72 1.2 0.9–1.4 1.9
2001–2010 6326284 613 9.7 8.9–10.5 2.3 46 0.7 0.5–0.7 1.2
1981–1990, 1991–2000, and 2001–2010. The incidence of the
5-year periods did not change our overall conclusions (data
not shown). Furthermore, to avoid chance variation, we
used 10-year periods in our calculations. Statistical analyses
were performed using SPSS 9.0 for Windows. Correlation
of diagnostic age (age at diagnosis) and delay (time from
onset to diagnosis) across three time periods was conducted
using Kruskal-Wallis tests [17] with Bonferroni adjustment
for multiple comparisons.With the Kruskal-Wallis test, a chi-
square statistic is used to evaluate the differences in mean
ranks to assess the null hypothesis that the medians are
equal across the groups. A 𝑃 value of < 0.05 with Bonferroni
correction was considered statistically significant.
3. Results
From 1 January 1981 to 31 December 2010, a total of 1617 MS
cases met the inclusion criteria in study districts (933 cases in
Seina¨joki and Vaasa and 684 cases in Pirkanmaa). A total of
1105 (68%) women and 512 (32%) men were included. RRMS
was observed in 1419 cases (89%) and PPMS in 198 cases
(11%). F/M ratios in RRMS were 2.1 (965 women, 454 men)
and in PPMS 1.2 (109/89).
Changes in age-adjusted incidences per 105 person-years
with 95% CIs for the three study periods 1981–1990, 1991–
2000, and 2001–2010 are presented in Table 1. A twofold
increase in RRMS (from 4.2 (3.7–4.6) to 9.7 (8.9–10.5)/105)
and a decrease in PPMS (from 1.2 (0.9–1.4) to 0.7 (0.5–0.7))
were observed. At the same time the female/male (F/M) ratios
in RRMS increased from 1.9 to 2.3 and decreased in PPMS
from 1.6 to 1.2.
In RRMS group the mean age at diagnosis was 36.3 and
in PPMS 45.3 years. We studied the age and gender effect by
disease course by calculating the F/M ratios in each ten-year
age group, presented in Figure 2 showing an exceptionally
high F/M ratio of 5 : 1 (𝑛 = 34/7 cases) inRRMS age group<20
years. After this the distribution showed an approximately
twofold ratio from 20 to 59 years in RRMS, while that in
PPMS was 1 : 1.
In addition to age and gender difference, the distribution
of onset symptoms showed a significant difference by disease
course (𝑃 = 0.000), shown in Figure 3. In RRMS, brainstem
(26%), visual (25%), and sensory symptoms (24%) were
equally distributed and showed a female preponderance: F/M
ratios were 2.0, 2.1, and 2.7. In PPMS, motor symptoms (total
53%) showed an F/M ratio of 0.8. (The distribution of onset
symptoms showed no regional difference, not shown.)
Incidences in both themedium-risk Pirkanmaa andwest-
ern high-risk region showed increasing RRMS, decreasing
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Figure 2: F/M ratios in ten-year age groups. F/M ratio in RRMS
remained about twofold or higher from 20 to 59 years and in PPMS
ratio was about 1 : 1, except for a slightly higher ratio in the 40–49 age
group. The F/M ratio in RRMS is significant in age group younger
than 20 years, where the ratio of women to men was 5 : 1 (𝑁 = 34/7
cases), and no PPMS cases were observed.
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Figure 3: Distribution of onset symptoms in RRMS and PPMS
groups diagnosed from 1981 to 2010.
PPMS, and parallel trends for men and women from 1981
to 2010 (Figures 4(a) and 4(b)). The increased incidence
of RRMS showed regional differences: F/M ratios increased
from 1.5, 1.9 to 2.3 in high-risk region, while ratios were stable
(2.8, 2.3, and 2.3) in Pirkanmaa. This was true also in PPMS
with the opposite downward incidence: F/M ratios declined
(1.6, 0.7 to 0.8) in the high-risk district and increased (1.6, 1.4,
and 2.6) at medium-risk district.
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Figure 4: RRMS and PPMS incidence trends in medium-risk district Pirkanmaa (a) and high-risk districts Seina¨joki and Vaasa (b) from 1981
to 2010.
Table 2: Use of MRI scans in the diagnostics of MS by disease courses (RRMS and PPMS) in the study cohort diagnosed from 1981 to 2010.
Period 1981–1990 1991–2000 2001–2010 Total 1981–2010
𝑁 % 𝑁 % 𝑁 % 𝑁 %
RRMS cases 280 526 613 1419
All scans/RRMS 113 40 446 85 599 97 1158 82
Brain 102 36 388 74 467 76 957 67
Spinal 5 2 13 2 20 3 38 3
Brain + spinal 6 2 45 9 112 18 163 12
PPMS cases 80 72 46 198
All scans/PPMS 16 20 56 78 43 93 115 58
Brain 9 11 33 46 30 65 72 36
Spinal 1 1 7 10 2 4 10 5
Brain + spinal 6 8 16 22 11 24 33 17
3.1. Case Ascertainment and Diagnostic Criteria. During the
thirty years of follow-up both diagnostic criteria and case
ascertainment have changed. Use of paraclinical tests in
case ascertainment showed an increasing use of MRI scans:
from 40% up to 97% in RRMS and from 20% to 93% in
PPMS (Table 2). Scans including both brain and spinal cord
remained low and pure spinal scans were rarely performed.
The number of normal findings in the first diagnostic MRI
scans was similar in the two groups (6.3% in RRMS and 8.6%
in PPMS, not shown). There was no difference in MRI use
between men and women (not shown).
Diagnostic cerebrospinal fluid (CSF) analysis has been
used constantly, performed in 92% (𝑛 = 1299) of RRMS
cases and 90% (𝑛 = 178) of cases with PPMS; no temporal
changewas seen (𝑃 = 0.4 in PPMS and 0.2 in RRMS). Positive
findings (increased IgG index > 0.6 and oligoclonal bands
in immunoelectrophoresis) were seen in 89% in RRMS and
91% in PPMS groups. The number of normal CSF findings
increased in the RRMS group from 5.4% to 12%. Evoked
potentials, including visual, brainstem auditory, and sensory
potentials, were used decreasingly. InRRMS (𝑛 = 337, 24%), a
positive result (prolonged latency) was seen in 76% (𝑛 = 256)
of all studied EPs. In PPMS (𝑛 = 61, 31%), EP was positive in
97% (𝑛 = 49).
We have observed a decreasing diagnostic delay from
onset symptoms to diagnosis in this cohort.Themedian diag-
nostic delay has decreased from 4.0 years to 2.0 years (chi-
square test,𝑃 < 0.001) during the study periods [14].This was
mainly explained by improved diagnostics inMS. Decreasing
delay was shown to concern especially RRMS course and
male PPMS in this study (Table 3). The Kruskal-Wallis tests
were used to compare the temporal relationship between
the mean ages at diagnosis and diagnostic delays within the
three ten-year periods from 1981 to 2010. Decreasing ages
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Table 3: Mean age at diagnosis and diagnostic delay (years) presented by disease course and gender during the study periods 1981–1990,
1991–2000, and 2001–2010.
Disease course
Period
RRMS PPMS
Female Male Female Male
Mean delay (y) Mean age (y) Mean delay (y) Mean age (y) Mean delay (y) Mean age (y) Mean delay (y) Mean age (y)
1981–1990 4 36 3 37 2 44 4 43
1991–2000 2 37 2 36 3 44 3.5 43
2001–2010 2 35 1 35 3 53 2.5 50
Table 4: RRMS andPPMS incidences (I) and total incidence per 105 person-years with 95% confidence intervals (CIs) by Poser andMcDonald
criteria in the whole study cohort from 2001 to 2010.
Criteria Poser McDonald
𝑁 % Incidence 95% CI 𝑁 % Incidence 95% CI
Disease course
RRMS 613 93 9.7 8.9–10.5 556 94 8.8 8.1–9.5
PPMS 46 7 0.7 0.5–0.9 35 6 0.6 0.4–0.8
Total 659 100 10.4 9.6–11.2 591 100 9.3 8.5–10.1
in RRMS were associated with decreasing diagnostic delays
among both men (𝑃 = 0.035) and women (𝑃 = 0.036) over
time. In PPMS group increasing ages for women associated
with increasing delays (𝑃 < 0.0001), while increasing ages
for men were observed in the presence of decreasing delays,
result being nonsignificant.
To study the effect of changes in diagnostic criteria, we
reevaluated cases diagnosed between 2001 and 2010 using
the McDonald criteria published in 2001 [10] and calculated
incidences for comparison with the group diagnosed with
Poser criteria. Results are shown in Table 4. In McDonald
group loss of 11 cases (24%) in PPMS and 57 cases (9%) in
RRMS was seen, mainly due to normal or lacking MRI scans
at the time point of first diagnosis (by Poser). However, the
resulting 10-year incidence rates were similar using both sets
of diagnostic criteria.
4. Discussion
Epidemiological observations in northern Europe [2] have
pointed to a rising female and RRMS incidence, which was
shown also here. During the thirty years of follow-up we
also observed opposite incidence trends in RRMS and PPMS,
characterized by differences in ages at diagnosis and distri-
bution of gender and initial symptoms. The observation on
decreasing age at diagnosis and diagnostic delay concerned
both genders only in RRMS. In case of PPMS, there was an
increase in age at diagnosis and a longer delay to diagnosis.
Delay was higher among women with PPMS, which may be
due to observed onset symptoms, which were more vague
and unspecific compared to motor symptoms observed more
often among men. However, together with the increasing
use of MRI, up to 93% in PPMS and 97% in RRMS, and
routine use of CSF in diagnostics, results indicate a more
precise recognition of MS and reflect improved differential
diagnostics, which are crucial in planning suitable treatment
strategies for MS patients.
Explanations for the increasing MS incidence include
increased awareness and improvements in case ascertain-
ment and diagnostic accuracy [13]. In this cohort we were
able to study the changes in case ascertainment during thirty
years and compare incidence rates using both the Poser and
McDonald criteria during the last decade 2001–2010 [10, 15].
A somewhat unexpected loss of 68 cases (4.2%) was seen
using the McDonald criteria—57 in RRMS and 11 in PPMS—
mainly due to normal or lacking MRI scans at the time
point of diagnosis by the Poser criteria. However, eventual
incidence rates were similar with the two sets of criteria.
We thus believe that the clinical use of McDonald criteria,
which underline the need ofMRI use inMS diagnostics, con-
founded neither the temporal nor the regional comparisons
and conclusions in this study.
Results during the last study decades 1991–2010 reflect
the facilitation of access to MRI. The standardization of the
performance and interpretation of MRI in the 2001 McDon-
ald criteria have promoted an earlier diagnosis of RRMS in
many cases of clinically isolated syndrome [18]. Nevertheless,
criteria were criticized for rejecting historical accounts of
symptoms and recommended the need for positive CSF for
the diagnosis of PPMS.Thismay result in underdiagnosing of
some cases and especially PPMS cases.The revision of criteria
in 2005 has had a minor effect in our results.
However, the generally increasing integration of MRI
into diagnostic work-ups seems to enhance the diagnosis
among cases showing clinical relapses at onset. The need for
early treatment [8] among these cases necessitates a reliable
diagnosis, which appears in this study. Our observation that
a lowPPMS incidencewas related to a somewhat less frequent
use of MRI raises the question of a possible underestimation
of PPMS cases during the follow-up. This is unlikely, as the
number of PPMS cases was already very low in the beginning
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of the follow-up. Furthermore, the high rate of initial motor
symptoms in PPMS, as was observed here, is associated with
a relatively rapid disability progression leading to diagnosis
[19–21]. The lengthy diagnostic delay and somewhat less
frequent use of MRI, however, indicate that diagnosis is
delayed in PPMS and it is diagnosed mainly on clinical
grounds. Based on these data, we suggest early and repeated
MRI in patients that present with symptoms consistent with
MS in order to reach a disease-course-specific diagnosis and
evaluate suitable therapy options.
The limitation in our study concerns the common classi-
fication problems in defining the clinical subtypes. Here, the
disease course was categorized as either relapsing-remitting
or primary progressive [16]. Recognition and diagnosis of
PPMS using diagnostic criteria that are predisposed to inac-
curacy, like the Poser criteria, have been criticized as leading
to an underestimation of cases, whereas use of theMcDonald
criteria has been questioned due to validity and sensitivity
issues [22, 23]. In general, themain issue in PPMS is the recall
bias for initial symptoms, which can remain unidentified
and lead to incorrect classification, regardless of the criteria
used. Another caveat is the misclassification of secondary
progressive cases as primary progressive, which is unlikely
in this study cohort, considering the generally low number
of PPMS cases and generally careful scrutiny of disease
evolution in clinical practice. Explanations for the results in
our former study [24] showing a tandem increase for the
two progression types reflect the nowadays improved case
recognition of PPMS, and, at the end of the day, this result
contradicted neither the assumptions nor the conclusions in
this study.
The strength of this study lies in a careful scrutiny of
frequent medical assessments during the 30-year follow-up,
which is believed to improve the reliability of the disease-
course recognition. MS is diagnosed and treated by neu-
rologists in public healthcare in Finland which is why we
have a full coverage of MS patients in this population-based
study. Furthermore, the neurological services and facilities
are homogenously distributed throughout Finland, and the
diagnostic work-up is convergent and based on International
and National Current Care Guidelines [25].
It has been suggested that the differential gender distribu-
tion in MS reflects epigenetic factors and gene-environment
interactions [26], including sex differences on the expression
of candidate genes on the X or Y chromosome [27]. Given
that the contributing genetic changes in populations are slow
ones, the increasing female incidence in MS, rheumatoid
arthritis in 1995–2007 [28], and other autoimmune diseases
[29] indicates a crucial role of globally acting changes that
affect autoimmune disease risk in the reproductive years
of life. Environmental factors affecting women, such as
contraception, diet, obesity, smoking, sunlight exposure, and
vitamin D deficiency [27], are among the relevant lifestyle
changes, as well as a higher age at first childbirth [30]
and fewer pregnancies over a lifetime [31, 32]. These effects
causing increased disease risk may be present already during
the fetal period and in the childhood, supported by the
fivefold F/M ratio among RRMS cases younger than 20
years as was seen in this study. This result corroborates
observations of a higher relapse rate among females and
the effect of age and disease duration on disease activity
[33].
It is, however, unclear how environmental factors are
shared between the two disease courses. To complicate
inference, it is thought that the different phenotypes in MS
are part of a disease spectrum modulated by individual
genetic predisposition and environmental influences. In the
case of RRMS, environmental factors that are able to cause
functionally relevant changes in gene expression [34, 35]
may be primarily associated with factors responsible for
inflammatory reactions of a putative autoimmune nature
in the central nervous system [36]. A better understanding
of the factors that underlie the differential gender and
disease-course distribution should shed more light on MS
susceptibility factors overall.
Regional MS risk in Finland shows east-west gradient,
and the high-risk region is located on the west coast. In
this study we have shown that increasing incidence concerns
exclusively RRMS cases in high-risk region Seina¨joki and
Vaasa. Recent genome-wide scanning (GWAS) in MS has
established the role of the HLA locus but also identified
common variants associated with MS with low odds ratios
[37]. To expose rare, high-impact alleles, a GWAS study
was conducted in the high-risk internal isolate Seina¨joki
district in Finland, where several large families with MS have
been observed. Results showed a STAT3 gene association
in MS [38], which implies a risk for another autoimmune
disease in this cohort and has also raised the hypothesis that
some genetic variants may be either more easily identified
or etiologically more relevant in certain isolated popula-
tions. Also, family studies of MS have shown an increased
risk of type 1 diabetes mellitus (DM), which also implies
that certain genetic variants may increase susceptibility to
autoimmune disease in general [39]. Childhood type 1 DM
incidence follows MS incidence temporally [40] and may
signal an increased penetrance of disease susceptibility genes
in autoimmune diseases that may be more easily identified in
genetic isolates or in families in high-risk regions of MS.
Increasing rates of relapsing MS in both medium- and
high-risk districts indicate that a more precise definition of
the genetic and environmental risk factors and their action
in MS is needed to provide a better understanding of the
underlying pathological processes and eventually to aid the
development of preventive and treatment strategies. We con-
clude that initiatives to improve the use of population-based
registers with linkages to independent national databases are
needed to generate large international cohorts with shared
demographic and clinical information [41].
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